Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan. Issue 38 (9th September 2022)

• Record Type: Journal Article
• Authors: Matsuura, Tomoka; Fukushima, Wakaba; Nakagama, Yu; Kido, Yasutoshi; Kase, Tetsuo; Kondo, Kyoko; Kaku, Natsuko; Matsumoto, Kazuhiro; Suita, Asae; Komiya, Eriko; Mukai, Emiko; Nitahara, Yuko; Konishi, Ayako; Kasamatsu, Ayane; Nakagami-Yamaguchi, Etsuko; Ohfuji, Satoko; Kaneko, Yukihiro; Kaneko, Akira; Kakeya, Hiroshi; Hirota, Yoshio
• Is Part Of: Vaccine. Volume 40:Issue 38(2022)
• Page Start: 5631
• Page End: 5640
• Publication Date: 2022-09-09
• Subjects: SARS-CoV-2 -- Vaccination -- Immunoassay -- mRNA vaccine -- Japan -- BNT162b2 -- anti-RBD antibody response -- Architect SARS-CoV-2 IgG II Quant -- Elecsys Anti-SARS-CoV-2 S; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.08.018
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Two BNT162b2 doses resulted in adequate anti-receptor-binding domain (RBD) antibody response. Anti- receptor-binding domain (RBD) titers varied by age but not sex and BMI. Anti-RBD titers by two assays 6 months after vaccination showed different kinetics. The results of single immunoassays should be interpreted with caution. Abstract: Background: Although several assays are used to measure anti-receptor-binding domain (RBD) antibodies induced after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, the assays are not fully comparable in practice. This study evaluated the immunogenicity of the BNT162b2 mRNA vaccine in healthy adults using two immunoassays. Methods: This prospective cohort study included SARS-CoV-2-naïve adults, predominantly healthcare workers, aged 20–64 years, who received two BNT162b2 vaccine doses between March and May 2021. Blood samples were collected before the first vaccination (S0), before the second vaccination (S1), 4 weeks after the second vaccination (S2), and 6 months after the second vaccination (S3). anti-RBD antibodies were measured using the Architect SARS-CoV-2 IgG II Quant (Abbott Laboratory) and Elecsys anti-SARS-CoV-2 S (Roche Diagnostics) assays. Results: Among the 385 participants, the geometric mean antibody titers (GMTs) on the Architect assay (AU/mL) were 7.5, 693, 7007, and 1030 for S0, S1, S2, and S3, respectively. The corresponding GMTs on the Elecsys assay (U/mL) were 0.40, 24, 928, and 659, respectively. The GMT ratio (S3/S2) was 0.15 on the Architect and 0.71 on the Elecsys assay. The correlation between antibody titers measured with the two assays were strong at all time points after vaccination (Spearman's correlation coefficient: 0.74 to 0.86, P < 0.01 for all). GMT was significantly lower in the older age group after vaccination (P < 0.01), with no significant differences according to sex. Seroprotection (≥5458 AU/mL on the Architect assay and ≥ 753 U/mL on the Elecsys) at each time point was 0 %, 1 %, 67 %, and 1 % on the Architect assay and 0 %, 1 %, 62 %, and 43 % on the Elecsys, respectively. Conclusions: Two BNT162b2 vaccine doses resulted in adequate anti-RBD antibody response, which varied by age. As the two assays showed different kinetics, the results of single immunoassays should be interpreted with caution.